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Introduction
Despite improved treatment options available, cardiovascular diseases, such as athero-
sclerosis, remain a leading cause of death in North America [1]. Atherosclerosis is the 
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Background: Statin drugs are one of the most commonly prescribed pharmaceuticals 
by physicians. By blocking the rate‑limiting step in the cholesterol biosynthesis path‑
way, statins inhibit cholesterol synthesis, which benefits patient health. However, since 
many other important cellular processes are regulated within this pathway, they may 
also be influenced by statin therapy. These pleiotropic effects of statins have not been 
fully investigated, but are believed to positively influence endothelial cells (ECs), which 
line the vasculature in a confluent monolayer. Few studies have considered the effect 
of blood flow on ECs and how this may augment EC response to statins.
Methods: In this study, the effect of statin treatment on ECs is investigated for cells 
stimulated with tumor necrosis factor alpha (TNF‑α), an inflammatory cytokine that 
promotes an atheroprone endothelium. Additionally, ECs are exposed to a physiologi‑
cally relevant wall shear stress (WSS) of 12.5 dynes/cm2 using a three‑dimensional tis‑
sue culture model to provide a realistic hemodynamic environment. ECs are analyzed 
for morphology using light microscopy as well as cytoskeletal structure and alignment 
using confocal microscopy. Statistical analysis is performed on the results using both 
the one‑way analysis of variance with Bonferroni post‑tests and the two‑tailed t test.
Results: We have shown that statin treatment caused cells to adapt to a rounded, 
atheroprone morphology, with a significantly higher shape index. Oppositely, TNF‑α 
stimulation caused cells to elongate to an atheroprotective morphology, with a signifi‑
cantly lower shape index. WSS and TNF‑α were unable to reverse any statin‑induced 
cell rounding or F‑actin disruption.
Conclusion: Further work is therefore needed to determine why statin drugs cause 
cells to have an atheroprone morphology, but an atheroprotective genotype, and 
why TNF‑α stimulation causes an atheroprotective morphology, but an atheroprone 
genotype. Despite the morphological changes due to statins or stimulation, ECs still 
respond to WSS. Understanding how statins influence ECs will allow for more targeted 
treatments for hypercholestemia and potentially other diseases.
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accumulation of cells, lipids, and extracellular matrix within blood vessel walls that can 
lead to the formation of an unstable plaque, causing heart attack or stroke [2–4]. High cho-
lesterol levels are one of many risk factors for developing atherosclerosis [5].
Clinically, statin drugs [inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) reductase] have been successful in reducing patient cholesterol 
levels [6–11], reducing the risk of heart attack and stroke. There are other benefits 
to statin therapy that the decrease in cholesterol alone cannot explain, called pleio-
tropic effects [10, 12–14]. These effects are believed to be regulated in side pathways 
of the cholesterol biosynthesis pathway [10, 15], which is responsible for cellular 
processes such as cellular movement, signaling, morphology, differentiation, and 
cytoskeletal remodeling [10, 16, 17]. Statin drugs are thought to positively influence 
endothelial cells (ECs), the cells that line the vasculature in a confluent monolayer 
[2, 12–14].
ECs are a dynamic interface between the blood and vascular tissue and play a pivotal 
role in disease formation. Dysfunction of the ECs in response to biochemical and hemo-
dynamic stresses can create an inflammatory phenotype associated with atherosclerosis 
[18, 19]. Early work on the pleiotropic effects of statins neglected the effect of these envi-
ronmental stimuli and instead focused on static and in vivo studies, reviewed by Liao 
and Laufs [20] and Sadowitz et  al. [21]. Recent work has shown that this response is 
altered in the presence of fluid wall shear stress (WSS) [22–25].
EC morphology is believed to be a key indicator of cellular health [17, 26, 27]. Elon-
gated ECs are believed to be healthy, as they are found in regions of the vasculature 
exposed to undisturbed flow and are less likely to become atherogenic [18, 28]. Oppo-
sitely, rounded ECs are thought to be unhealthy as they are found in regions of disturbed 
blood flow, such as around curvature or bifurcations, where atherosclerotic lesions are 
likely to occur [2, 18, 28–31]. Both EC morphology and F-actin cytoskeleton structure 
are regulated within the cholesterol biosynthesis pathway [32, 33], and may therefore be 
influenced by statin treatment. Indeed, recent work published by our lab showed that 
ECs treated with statin drugs became rounded with a fragmented F-actin cytoskeleton 
when compared to an untreated control [25]. This process may be influenced by the 
activity of the small GTPase RhoA [28, 34], regulated within the cholesterol biosynthesis 
pathway [10, 15].
As atherosclerosis is an inflammatory disease, we have continued our studies by look-
ing at the response of an inflamed endothelium to statin therapy. Tumor necrosis fac-
tor alpha (TNF-α) is implicated in various inflammatory diseases and is commonly used 
to simulate an inflamed, atheroprone EC phenotype [35, 36]. TNF-α is also believed to 
influence the EC cytoskeleton through RhoA activation [37]. Here, we describe how EC 
morphology and F-actin cytoskeletal arrangement is affected when TNF-α stimulated 
cells are treated with simvastatin, under static and flow conditions.
Methods
The methods used here are based upon methods previously described elsewhere [22–25], 
but will be summarized briefly.
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Tissue culture model preparation
Flexible, transparent tissue culture models were prepared by curing Sylgard® 184 silicone 
elastomer (Dow Corning) around a 2  mm diameter stainless steel rod (McMaster-Carr, 
1256T999) in a Plexiglas mold for 24 h at 45°C. To sterilize for cell culture, models were 
boiled in reverse osmosis water for 30 min. A suitable surface for cell growth was created 
by coating the inner lumen of the model with 40 μg/mL fibronectin (Sigma, F0985). The 
models were sealed using PVDF filters (Fisher, 097203) and attached to a LabQuake rotor 
(Barnstead/Thermolyne) and left to rotate overnight within an incubator set at 37°C and 
5% CO2 (Thermo Scientific).
Cell culture
Human abdominal aortic endothelial cells (HAAECs) from a 20-year-old male (Coriell 
Institute for Medical Research, AG09799) were obtained from the supplier and expanded 
as per supplier protocol. For individual experiments, 1 mL of frozen HAAECs was thawed 
and cultured within a T175 flask (VWR, 82050-872) coated with gelatin (Sigma, G2500) 
using basal PromoCell media with SupplementMix (PromoCell, C-22010) containing 
0.02 mL/mL fetal calf serum, 0.004 mL/mL endothelial cell growth supplement, 0.1 ng/
mL human recombinant epidermal growth factor, 1  ng/mL human recombinant basic 
fibroblast growth factor, 90 μg/mL heparin, and 1 μg/mL hydrocortisone, with 10% fetal 
bovine serum (Invitrogen, 26140-079) and 1% penicillin–streptomycin (Invitrogen, 15140-
122). The media was changed every 48 h and HAAECs were split into 4 T175 flasks after 
4  days when they became confluent. HAAECs were seeded into the fibronectin-coated 
models at passage 5, with a concentration of 1.25 × 106 cells/mL, and left on the rotor for 
24 h to create a confluent monolayer of cells within the tissue culture models.
Solution preparation
Simvastatin (Sigma, S6196), mevalonate (Sigma, M4667), and TNF-α (Cedarlane Labora-
tories, 300-01A) were obtained from the suppliers and stock solutions of 0.5 mM simvasta-
tin, 50 mM of mevalonate, and 0.002 mg/mL TNF-α were prepared. These stock solutions 
were added to either the perfusion media, or within the lumen of static models, to obtain 
the final working concentrations of 10 μM simvastatin, 200 μM mevalonate, and 10 ng/
mL TNF-α. MTT assays were used to ensure no significant cell death due to simvastatin, 
mevalonate, or TNF-α treatment (unpublished data). These particular concentrations were 
chosen to elicit a reproducible response in vitro [24], although they are higher than a typi-
cal clinical dose [38].
Perfusion experiment
A flow diagram of the experimental time line is shown in Figure 1. A flow loop was cre-
ated within an incubator to ensure a proper environment for the cells was available for 
the duration of the experiment. The flow loop consisted of tubing (Cole Parmer), a peri-
staltic pump (Ismatec), custom stainless steel flow dampeners, and a media reservoir with 
a multi-hole cap. Both static and perfused models were analyzed. 6 h of preshearing was 
used in these experiments to first elongate the perfused cells to a morphology consistent 
with those found within the blood vessel of a patient starting statin treatment. For static 
models, the cells were not sheared for 6 h, but were instead kept static with fresh media.
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All perfused models were sheared at 12.5 dynes/cm2, a hemodynamically relevant level 
of WSS [29]. At t = 0 h, perfused models were introduced into the flow loop, and static 
models received new media. For perfused models being treated with TNF-α, 10 ng/mL 
TNF-α was introduced at this time. Static models had no TNF-α addition at this time. 
At t = 6 h, static models had a media change to introduce the statin solutions. For the 
perfused models, statin solutions, with or without 10 ng/mL TNF-α, were added directly 
to the perfusion media. A control with no statins was run in parallel, with or without 
10 ng/mL TNF-α. The experiment was continued for a further 24 h of treatment time. 
At t = 30 h, the models were disconnected from the flow loop. All models were washed 
three times with 1× PBS, fixed with 1% paraformaldehyde (Sigma-Aldrich, P6148) for 
20 min, and stored at 4°C until analysis.
Tissue culture model analysis
Models were analyzed for both EC morphology and F-actin cytoskeleton structure. For 
morphology analysis, the models were cut into 1 cm sections and then cut in half through 
the lumen. The bottom half of the model was analyzed by staining the EC nucleus with 
a 4% solution of crystal violet (BD Biosciences, 212525) in 1× PBS for 9 min and viewed 
under a light microscope (Leica Microsystems, DMIL Microscope) with digital camera 
(Leica Microsystems, Leica DC300). A single image was taken of each model piece, with 
ten representative ECs analyzed from each image. Images were analyzed using Photoshop 
(Adobe) and a MATLAB® (Mathworks) code to analyze the shape index (SI), a metric that 
ranges from 0 to 1 [39–42], describing how rounded the cell is; the closer the SI is to 1, 
the rounder the cell. The code recognizes the boundaries of the chosen representative cell 
based upon pixel intensity to determine the area, perimeter, and shape index of the EC 
nucleus, routinely used to quantify cell morphology [25, 39, 43].
Figure 1 Experimental timeline detailing the endothelial cell model preparation, perfusion experiment set 
up, and statin treatment.
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To analyze the F-actin cytoskeleton, 1 cm model sections were cut and the ECs were 
blocked and permeabilized with 0.1% Triton™ X-100 (Sigma, T8787) at room tempera-
ture for 5 min. ECs were washed and then dyed with phalloidin-conjugated Alexa Fluor® 
647 (Invitrogen, A22287), at a 1:40 dilution in 1× PBS with 1% bovine serum albumin 
(Sigma-Aldrich, A7906) at room temperature. ECs were rinsed and the model was fur-
ther cut so that only the bottom of the channel remained. The model piece was mounted 
within a cover slip bottomed petri dish (MatTek, CSGK) using a 0.2% Dabco (Sigma, 
D2522) solution in glycerol. A laser scanning confocal microscope (Zeiss, LSM 510) with 
Zen (2008) software (Zeiss) was used to image the ECs with a 10×/0.3 DICI or 20×/0.5 
DICII objective lens. Image analysis was completed with Photoshop (Adobe) and ImageJ 
(National Institutes of Health).
Statistical analysis
Each experiment was performed independently in triplicate. Prism™ 5 (GraphPad) was 
used to analyze the data. One-way analysis of variance (one-way ANOVA) with Bonferroni 
post-tests or unpaired two-tailed t tests were used. A P value of less than 0.05 was consid-
ered to be statistically significant.
Results
TNF‑α elongates ECs under static conditions
Stimulation with 10 ng/mL TNF-α for 24 h caused a significant decrease in the SI when 
compared to the non-stimulated, static control, Figure 2 (P < 0.001, one-way ANOVA with 
Bonferroni post-tests). Visually, ECs appeared more elongated, Figure 3a.
Figure 2 For each condition considered, the addition of 12.5 dynes/cm2 of steady wall shear stress caused a 
significant decrease in the endothelial cell shape index when compared to static ECs, ***P < 0.001 (two‑tailed 
t test). The addition of 10 μM simvastatin caused a significant increase in the endothelial cell shape index 
for both non‑stimulated and TNF‑α stimulated endothelial cells, for both static and flow conditions when 
compared to the vehicle control condition, +++P < 0.001 (one‑way analysis of variance with Bonferroni post‑
tests). Stimulation with 10 ng/mL TNF‑α caused a significant decrease in the endothelial cell shape index 
when compared to non‑stimulated endothelial cells for all conditions considered, and for both static and 
flow conditions, ^^^P < 0.001, ^^P < 0.01 (one‑way analysis of variance with Bonferroni post‑tests),>>>P < 0.001 
(two‑tailed t test). For Sim + TNFa: N = 9; all other conditions: N = 10. These values are reported as the 
mean ± standard error. Control vehicle control, Sim simvastatin, Mev mevalonate, TNFa TNF‑α.
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TNF‑α stimulated ECs respond to WSS and elongate
When ECs were stimulated with 10  ng/mL TNF-α at a WSS of 12.5 dynes/cm2, there 
was a significant decrease in SI when compared to the non-stimulated, perfused control, 
Figure 2 (P < 0.001, one-way ANOVA with Bonferroni post-tests). Visually, ECs appeared 
more elongated, Figure 3b.
Statin drugs round TNF‑α stimulated ECs under static conditions
A significant increase in the SI was observed when TNF-α stimulated ECs were treated 
with 10 μM simvastatin under static conditions when compared to the TNF-α stimulated, 
static control cells, Figure 2 (P < 0.0001, unpaired two-tailed t test). Visually, ECs appeared 
more rounded, Figure 3c.
Statin treated and TNF‑α stimulated ECs respond to WSS and become rounded
Stimulated ECs exposed to 12.5 dynes/cm2 of WSS and treated with 10 μM simvastatin 
had a significantly higher SI than the TNF-α stimulated, perfused, control cells, Figure 2 
(P  <  0.001, one-way ANOVA with Bonferroni post-tests). Visually, ECs appeared more 
rounded, Figure 3d.
Steady WSS and TNF‑α stimulation have similar impacts on EC SI
When non-stimulated ECs exposed to flow and TNF-α stimulated ECs left under static 
conditions were compared, there was no significant difference observed, Figure 2 (P > 0.05, 
one-way ANOVA with Bonferroni post-tests).
Figure 3 Endothelial cells stained with 4% crystal violet, a nuclear stain, and imaged at ×10 magnification. 
Scale bar represents 100 μm. All images are of endothelial cells that have been stimulated with 10 ng/mL 
TNF‑α. Flow is in the vertical direction. a static, control; b flow, control; c static, simvastatin; d flow, simvastatin; 
e static, simvastatin and mevalonate; f flow, simvastatin and mevalonate.
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Both TNF‑α stimulation and steady WSS are required to abrogate all statin effects on EC SI
There is no significant difference in EC SI when the TNF-α stimulated ECs were treated 
with 10 μM simvastatin and exposed to 12.5 dynes/cm2 of WSS when compared to the 
static control, Figure 2 (P > 0.05, unpaired two-tailed t test).
TNF‑α stimulation does not abrogate statin‑induced F‑actin cytoskeleton disorganization
When TNF-α stimulated ECs were treated with 10 μM simvastatin, the F-actin cytoskele-
ton became fragmented and disorganized. This was observed for both static and flow con-
ditions, Figure 4c and d.
Mevalonate abrogates the morphological change due to statin treatment of TNF‑α 
stimulated ECs under static and flow conditions
When TNF-α stimulated ECs were treated with both 10  μM simvastatin and 200  μM 
mevalonate there was no significant difference from the TNF-α stimulated control cells, 
under both static and perfused conditions, Figure 2 (one-way ANOVA with Bonferroni 
post-tests). Visually, ECs appeared to have the same morphology as the control cells, 
Figure 3e and f.
Mevalonate abrogates the change in F‑actin cytoskeletal arrangement due to statin 
treatment of TNF‑α stimulated ECs under static and flow conditions
When TNF-α stimulated ECs were treated with both 10  μM simvastatin and 200  μM 
mevalonate, the statin-induced F-actin cytoskeleton fragmentation did not occur. This was 
observed for both static and flow conditions, Figure 4e and f.
Figure 4 Endothelial cell F‑actin cytoskeleton stained with phalloidin conjugated Alexa Fluor® 647 and 
imaged using confocal microscopy. Scale bars represent 50 μm. All images are of endothelial cells that have 
been stimulated with 10 ng/mL TNF‑α. Flow is in the vertical direction. a static, control; b flow, control; c static, 
simvastatin; d flow, simvastatin; e static, simvastatin and mevalonate; f flow, simvastatin and mevalonate.
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Discussion
In this work, we investigated the effect of simvastatin on an inflamed endothelium. We 
show that ECs treated with simvastatin or stimulated with TNF-α are still able to sense and 
respond to WSS. We quantified the influence that 12.5 dynes/cm2 of steady WSS, statin 
treatment, and TNF-α stimulation has on HAAEC morphology within three-dimensional 
tissue culture models. As in accordance with other published literature [40, 42, 44], we 
have observed an elongation of cells, Figure 3, and a significant decrease in EC SI,  Figure 2, 
with the presence of a physiologically relevant WSS [29] of 12.5 dynes/cm2 when com-
pared to the static control. We observed this trend for all of the conditions considered: 
with and without statin treatment, with or without mevalonate treatment, and with or 
without TNF-α stimulation.
It is well established that in the presence of WSS, ECs will elongate and align in the 
direction of flow [18, 40, 42, 44]. The elongation observed when ECs are exposed to 
steady WSS [45, 46] is believed to be a result of increased RhoA activity, which is known 
to be involved in cytoskeletal remodeling [28, 34]. The presence of an intact, elongated 
F-actin cytoskeleton, aligned in the direction of flow in response to WSS has been previ-
ously documented [42, 43].
We have also observed that EC stimulation with TNF-α causes a significant elonga-
tion (reduction in SI) visually and quantitatively under both static and flow conditions, 
 Figures  2 and 3. There is a significant difference in SI observed between stimulated 
ECs with the addition of flow, which suggests that the cells are still responding to WSS 
despite the changes caused by stimulation. An interesting observation in this work is 
that both WSS and TNF-α stimulation have similar impacts on EC SI, Figure 2. There 
is no significant difference in the SI between non-stimulated ECs exposed to flow and 
static TNF-α stimulated ECs. This is true for each condition considered: control, simvas-
tatin, and simvastatin and mevalonate. This suggests that the effect of WSS and TNF-α 
stimulation on RhoA activation is similar in magnitude.
The observed elongation is likely related to the EC cytoskeleton. The EC cytoskeleton is 
believed to mechanotransduce physical stimuli through the cell to biochemical changes 
[28, 47]. Research has shown that TNF-α stimulation causes the F-actin cytoskeleton to 
elongate and form dense actin bands [37, 48]. Additionally, TNF-α stimulation has also 
been shown to increase RhoA expression in ECs [37, 48] and other cell types [49], lead-
ing to the same effects as for the WSS-dependent RhoA activation. These effects appear 
additive, in that we have observed a significant decrease in EC SI between ECs exposed 
to 12.5  dynes/cm2 of steady WSS and TNF-α stimulated ECs exposed to 12.5  dynes/
cm2 of steady WSS, Figure  2. This finding is consistent with that of Stroka et  al. [50] 
who reported an increase in EC aspect ratio as well as elongation and alignment of the 
F-actin cytoskeleton with TNF-α stimulation. We also compared how the morphol-
ogy of simvastatin treated ECs differed with TNF-α stimulation under both static and 
flow conditions, Figure 3. We observed that there is a significant increase in EC SI when 
TNF-α stimulated ECs are treated with 10 μM simvastatin, under both static and flow 
conditions, when compared to the stimulated control, Figure 2. We have also observed 
a significant decrease in EC SI between the non-stimulated and stimulated simvastatin 
treated ECs under static and flow conditions, Figure 2. This implies that the TNF-α stim-
ulation still has an effect on simvastatin treated ECs.
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It is believed that the activation of RhoA, by either steady WSS or stimulation with 
TNF-α, causes the F-actin cytoskeleton to become elongated and stretches out the cell 
[48]. Studies have shown that there is a link between statins and RhoA through the cho-
lesterol biosynthesis pathway [10, 51], with statin treatment lowering RhoA activity 
[20, 52]. Statins work by blocking the rate-limiting step in the cholesterol biosynthesis 
pathway—the conversion of HMG-CoA to mevalonate. This prevents the formation of 
cholesterol, but also influences many intermediates within the pathway. Two important 
isoprenoid molecules are formed within this pathway, GGPP and FPP [10, 15, 51, 53], 
which serve as lipid attachments for small GTPases, such as Rho and Rac, which require 
posttranslational modifications [15, 54]. A decrease in FPP and GGPP will decrease 
the amount of active RhoA [12, 48, 55]. Ultimately, this decrease in protein expres-
sion is believed to lead to statin-induced F-actin cytoskeleton fragmentation and dis-
organization shown in both ECs [25] and stromal cells [52], leading to a round cellular 
morphology.
In this work, we have observed a decrease in EC SI with TNF-α stimulation, but an 
increase in EC SI with statin treatment, even with stimulation and WSS, Figure 2. Mor-
phology has generally been correlated to cellular health. Researchers have found that in 
atheroprone regions of the vasculature, such as around bifurcations or curvature where 
there may be disturbed flow, ECs appear to have a cobblestone morphology [31, 42]. In 
contrast, ECs found in atheroprotective regions of steady flow appear elongated and 
have an atheroprotective genotype [18, 42, 56, 57]. This has led to the assumption that 
healthy ECs are elongated and unhealthy ECs are rounded and cobblestone. We have 
observed that TNF-α stimulation and WSS promote what is typically considered to be a 
healthy, atheroprotective EC morphology. We have also observed that statins influence 
the ECs to become rounder, which is typically indicative of an atheroprone morphol-
ogy. This is counter-intuitive, as statins are thought to be beneficial to ECs and pro-
mote an atheroprotective genotype, and TNF-α stimulation is thought to promote an 
atheroprone genotype as it is commonly used as an inflammatory cytokine to simulate 
an atheroprone EC phenotype, such as for adhesion experiments [36]. Protein expres-
sion also indicates that TNF-α stimulation of ECs leads to an inflammatory phenotype 
as atheroprone markers, such as ICAM-1 and VCAM-1, are significantly increased [23, 
24, 58]. We observed that the statin induced fragmentation of the EC F-actin cytoskel-
eton was not abrogated by either WSS or TNF-α stimulation on their own, although we 
believe them to both function through the cholesterol biosynthesis pathway.
In our work, we use mevalonate to ensure that the effects that we are observing due to 
statin treatment are regulated within the cholesterol biosynthesis pathway [59]. Indeed, 
we observe that there is no significant difference between the control condition and the 
simvastatin and mevalonate condition for both EC morphology, Figures  2 and 3, and 
F-actin cytoskeletal arrangement, Figure 4. This is true for both static and flow ECs, in 
accordance with previous results from our lab [22–25] and other literature sources [59–
61], as well as non-stimulated and stimulated ECs. Mevalonate alone had no significant 
effect on cell proliferation, shape or F-actin organization (data not shown).
We have shown that both statin therapy and TNF-α stimulation induce changes in the 
cell, but that ECs still respond to WSS despite the statin-induced fragmentation. These 
results suggest that morphology and the state of the F-actin cytoskeleton may not be a true 
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indicator of cellular health, and alternative methods of analysis should be considered. It 
also shows that EC mechanotransduction occurs despite changes in the F-actin cytoskel-
eton. Future work will focus on making a quantitative link between statin drugs and RhoA 
regulation, with the hopes of designing more specific and improved statin drugs.
Conclusion
In this work, we studied how an inflamed (TNF-α stimulated) endothelium responds to 
steady WSS when treated with 10 μM of simvastatin. Statin treatment or TNF-α stimu-
lation did not hinder the ability for ECs to sense and respond to WSS despite significant 
alterations in the F-actin cytoskeletal structure. Although statin drugs are thought to be 
beneficial to ECs, they caused the cells to adapt a rounded morphology and fragmented 
F-actin cytoskeleton, usually considered unhealthy. Conversely, TNF-α stimulation caused 
the cells to become more elongated, which is usually indicative of a healthy, atheropro-
tective EC. Neither WSS nor TNF-α stimulation was able to abrogate the statin-induced 
rounding of cells, or the F-actin cytoskeleton rearrangement due to statin treatment. ECs 
were still able to respond to WSS by elongating despite changes in the F-actin cytoskeleton 
structure. This work suggests that an alternate method of determining cellular health is 
necessary, as cellular morphology does not always correlate with cellular phenotype.
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